Fresh analysis reveals that individuals who stop using popular GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds far faster than those who stop conventional lifestyle regimens.
Research printed in a leading medical journal demonstrates that while overweight people can lose substantial amounts of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing such drugs should be informed of the potential of fast rebound weight gain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
This pace of regain implies a return to original mass within about 18 months.
Comparing Approaches
The analysis, which examined dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with other pills.
Scientists point out that individuals who shed pounds through lifestyle changes alone typically see a less rapid creep back—around 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Nutrition scientists propose the way of the injections is key to understanding the accelerated regain.
The injections mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal may cause the system to produce less of its endogenous hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Issue?
Medical guidelines advise the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, considering the high risk of weight regain, the treatment is often long-term.
This opinion is echoed by drug manufacturers, who state that the findings "underscore the long-term nature of excess weight," akin to managing diseases like diabetes.
Patient Testimonies
People who have discontinued the jabs explain a intense resurgence of appetite.
"It felt as if a trigger that goes on and you become starving," recalled a patient.
This difficulty is exacerbated if users have not developed permanent lifestyle or habit modifications during therapy.
Significant Use
Recent estimates suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is higher among women than males.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians caution that while these medications are potent agents for weight loss, they are not a magic cure and lasting health benefits relies on integrated behavioural support.
